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ABSTRACT
This paper reviews the involvement of the serotonergic system in controlling food intake 
and satiety. It is of great interest to understand this system relevance in physiologic con-
trol of energy balance and obesity. Over 35-year research suggests that serotonin (5-HT) 
plays an important role in satiety. Thus, serotonergic system has been a viable target in 
weight control. 5-HT shows control over hunger and satiety through different receptors 
with discrete functions. 5-HT2C receptor seems to be the most important one in the 
relationship between food intake and energy balance. In this review, serotonergic system 
mechanisms involved in food intake control and satiety will be discussed.
Keywords: Serotonin; serotonin 5-HT2C receptor; appetite regulation; satiety response; 
hypothalamus.
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INTRODUCTION
Serotonin (5-HT) plays an important role in nervous sys-
tem with different functions, such as some hormone re-
lease, sleep, body temperature, and appetite regulation, 
mood, motor activity, and cognitive functions. Changes in 
levels of 5-HT (low levels or disturbed receptor signaling) 
have been related to increased craving for sweets and car-
bohydrates. If a person has a normal 5-HT level, he/she 
can achieve satiety and control over sugar intake more ea-
sily. This neurotransmitter proper level in the brain depen-
ds on food tryptophan (serotonin precursor amino acid) 
and carbohydrate intake1-3.
Over 35-year research suggests that 5-HT plays an im-
portant role in satiety. Thus, serotonergic system has been 
a viable target in weight control. Drugs inhibiting 5-HT 
uptake have been increasingly used to achieve weight loss 
in obesity treatment, as they enhance satiety power in food 
post-intake and post-absorption components. Several se-
rotonin receptor subtypes were identied, with 5-HT1B 
and 5-HT2C being recognized as satiety inductors3-6. Our 
aim is to review the role of brain serotonergic system in 
controlling food intake and satiety. 
SEROTONERGIC SYSTEM
5-HT or 5-hydroxytryptamine is an indolamine, a hydro-
xylation and carboxylation by-product of amine acid tryp-
tophan. It is produced in raphe nuclei and  released throu-
ghout the brain. 5-HT is a neurotransmitter and as such, 
it serves to lead the transmission from one cell (neuron) 
to another. 5-HT is secreted by serotonergic neurons and 
exerts its activity on postsynaptic neuron receptors7-9.
Concentrations of brain 5-HT are related to behavior 
and mood changes, anxiety, aggressiveness, depression, 
sleep, fatigue, and even appetite suppression7,10.
5-HT has a behavior inhibiting effect, as well as a gen-
eral modulating effect on psychic activity. Therefore, 5-HT 
inuences almost all brain functions by either inhibiting 
or stimulating gamma-aminobutyric acid (GABA). This 
is how 5-HT regulates mood, sleep, sexual activity, appe-
tite, circadian rhythm, neuroendocrine functions, body 
temperature, pain sensitivity, motor activity, and cognitive 
functions7,8.
The carrier of 5-HT (5-HTT) is responsible for reup-
take of 5-HT in serotonergic nervous endings. Studies 
have shown that inhibition of 5-HTT, by increasing 5-HT 
postsynaptic stimulation, reduces food intake and body 
weight gain in rats and humans11,12.
FOOD NEUROMODULATION
A number of peptides act as neurotransmitters or hormo-
ne peptides by either increasing or reducing food intake. 
Feeding is also under a central system control regulated 
by a delicate balance between monoamines and neuro-
peptides13-15. Levels and possible functions of several neu-
rotransmitters are inuenced by dietary precursor stores. 
Main neurotransmitters include biogenic amines (5-HT, 
dopamine, noradrenaline, histamine), formed from tryp-
tophan, tyrosine, and histidine, as well as acetylcholine 
and glicine, which can be constituted from choline and 
threonine. The effects of precursors may be su cient to 
inuence mood and behavior in some circumstances, and 
administration of puried dietary components is a partial 
means to alter the metabolism of neurotransmitters in ex-
perimental or therapeutic procedures in animals and hu-
mans7,13,14.
5-HT activity, also involved in food intake behavior 
modulation, is assessed through level measurement of its 
major metabolite, 5-hydroxyindolacetic acid (5-HIAA). In 
patients with anorexia nervosa, 5-HT concentration is re-
duced, while in treated patients it is above average values 
in controls. Reduced 5-HT could be related to reduced es-
sential amine acid intake, including tryptophan, as well as 
reduced serotonergic receptor (5-HT2C) sensitivity14,15.
Animal studies suggest that 5-HT is also involved in 
food intake control, with serotonin high levels reducing 
total energy intake or selectively reducing carbohydrate 
selection over protein3,13.
Among various species, in different experimental con-
ditions, there is strong evidence that the increased activ-
ity of postsynaptic serotonergic receptors  subsequently 
causes reduction in food intake over a meal and changes 
the feeding pattern. The same evidence is available for 
5-HT anorectic role, particularly as a response to unbal-
anced amine acid diets13,16,17.
If 5-HT level is normal, the subject is more easily satiate 
and sugar intake is more easily inhibited, he/she feels more 
easily full and has a better control over sweet craving3,8,18.
Drugs that inhibit the uptake of neurotransmitters 
5-HT allowing them to remain in greater quantities and 
for a longer time in the synaptic cle promote a greater 
feeling of satiety and, in experimental studies, demon-
strate increased basal metabolism. Drugs as sibutramina, a 
satiety agent providing better hunger control (notably for 
sweets), are increasingly used in weight loss diets. Drugs 
inhibiting serotonin uptake selectively, such as uoxetine 
and sertraline, also reduce food intake, but they are not 
indicated in obesity treatment because of their nonspecic 
effect in reducing weight and weight regaining is observed 
in long-term studies6,17-19.
5-HT PHYSIOLOGICAL ASPECTS IN FOOD INTAKE AND 
SATIETY
5-HT exhibits control over hunger and satiety through 
several receptors with different functions. There are seven 
different families of 5-HT receptors, and in some of these 
families there are many receptor subtypes, mainly 5-HT1 
and 5-HT2 receptors. These receptors are responsible 
for the reduced food intake associated with serotonergic 
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agonist injection in paraventricular nucleus using quipazine, 
meta-chlorophenylpiperazine, and d-norfenuramine20-27.
5-HT2C receptor seems to be the most important in 
the relationship between food intake and energy balance. 
Mice devoid of that gene become obese and epileptic, 
whereas agonists acting on 5-HT2C receptor produce re-
duced food intake5,21-26.
Acting via 5-HT2C receptor, 5-HT directly acti-
vates pro-opiomelanocortin (POMC) cleavage. Through 
5-HT1B receptor, serotonin hyperpolarizes and inhibits 
the neuropeptide Y (NPY) and the agouti-related protein 
(AgRP) at the arcuate nucleus, depressing gabaergic in-
hibiting transmission of a-melanotropin (a-MSH) and the 
cocaine and amphetamine regulated transcript (CART). 
These associated mechanisms produce satiety and thermo-
genesis stimulation and that is why these receptors have 
been investigated as pharmacotherapeutic goals in obesity 
treatment17,30-32.
5-HT, through 5-HT1B receptor action, modulates 
endogenous release of both agonists and antagonists of 
melanocortin receptors, which are a part of the major 
components of body weight homeostasis control circuit. 
Melanocortin pathway is essential for hypophagia in sero-
tonergic compounds. Recent research have claried that 
melanocortina receptors 4 (MC4) are the key inuencing 
appetite3,17,23,33.
5-HTC2 receptor agonist BVT.X reduces signi-
cantly food intake without changing locomotor activity 
or oxygen consumption in obese and lean rats. Extend-
ed BVT.X infusion in obese rats increases signicantly 
POMC mRNA and reduces body weight, body fat, and 
food intake. Mice lacking MC4 were used to assess mel-
anocortina functional importance in BVT.X effect on 
food behavior. The animals did not show any sensitivity 
to BVT.X-induced hypophagia, demonstrating MC4 re-
ceptor is a 5-HT2C agonist-depending pathway exerting 
effects on food intake. Extended BVT.X treatment pro-
motes weight loss and reduced body fat3,31.
The cannabinoid system also shows an interaction 
with serotonergic system. These systems can synergisti-
cally modulate food behavior. Further studies character-
izing 5-HT and cannabinoid receptor 1 (CB1) are required 
to identify mechanisms underlying interactions between 
cannabinoid and serotonergic systems5.
More recently, 5-HT2C receptor role in glucose ho-
meostasis was also reported in rodents. Pharmacological 
and genetic studies have shown direct 5-HT2C effects on 
glucose homeostasis. Serotonin uptake inhibitor-treated 
rats were demonstrated to have glucose tolerance im-
provement. The interaction between serotonin and leptin 
in glucose homeostasis makes serotonergic system a possi-
ble target in diabetes mellitus and obesity management34-36.
In conclusion, the serotonergic system shows control 
over hunger and satiety through various receptors with 
different functions. 5-HT2C receptor seems to be the most 
important receptor in the relationship between food in-
take and energy balance. This system is clearly important 
in controlling food intake and satiety and its evident syn-
ergistic interaction between different pathways, speci-
cally 5-HT2C, POMC, and MC4, in regulating the energy 
balance.
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